Author Topic: Vascular comorbidity in MS and general population--differing trends  (Read 53 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8561
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Neurology, May 2016. A link to the entire article is given below.

Differing trends in the incidence of
vascular comorbidity in MS and the
general population

Ruth Ann Marrie, MD, PhD; John Fisk, PhD; Helen Tremlett, PhD; Christina Wolfson, PhD; Sharon Warren, PhD;
James Blanchard, PhD; Scott B. Patten, MD, PhD; for the CIHR Team in the Epidemiology and Impact of Comorbidity
on Multiple Sclerosis

Departments of Internal Medicine (RAM) and Community Health Sciences (RAM, JB), University of
Manitoba, Winnipeg; Departments of Psychiatry and Medicine (JF), Dalhousie University, Halifax; Department
of Medicine (Neurology) (HT), University of British Columbia, Vancouver; Department of Epidemiology
and Biostatistics and Occupational Health (CW), McGill University, Montreal; Faculty of Rehabilitation
Medicine (SW), University of Alberta, Edmonton; and Department of Community Health Sciences (SBP),
University of Calgary, Canada.


Although the adverse effects of vascular
comorbidities are increasingly recognized in multiple
sclerosis (MS), the epidemiology of these
conditions remains poorly understood.


Using population-based administrative data, we identified
44,452 Canadians with MS and 220,849
age-, sex- and geographically matched controls. We
applied validated definitions to estimate the incidence
of diabetes, hypertension, hyperlipidemia, and ischemic
heart disease (IHD) from 1995 to 2005.


Of the MS cases, 31,757 (71.4%) were in female
participants, with a mean (SD) age at the index
date of 43.8 (13.7) years.

Over time, the age-standardized
incidence of diabetes rose more in the
MS population (incidence rate ratio [IRR] per year
1.06; 95% confidence interval [CI] 1.031.08) than
in the matched population (IRR per year 1.02; 95%
CI 1.011.03).

Temporal trends in the age-standardized incidence of hyperlipidemia, hypertension, and IHD were similar in both populations. Among those aged 2044 years, the
incidence of IHD was higher in the MS population (IRR 1.59; 95% CI 1.192.11).

The increased incidence of IHD in the MS population was attenuated among those aged 60 years and older (IRR 1.01; 95% CI 0.971.06).


The incidence rates of diabetes, hypertension, and hyperlipidemia are rising within the MS population. Programs to systematically prevent and treat these conditions are needed.

The entire article can be seen here.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post July 09, 2017, 02:07:47 pm
by agate
0 Replies
Last post November 10, 2017, 10:48:21 am
by agate
0 Replies
Last post March 21, 2018, 02:46:25 pm
by agate
0 Replies
Last post July 24, 2018, 02:34:13 pm
by agate
0 Replies
Last post August 16, 2019, 09:07:55 am
by agate